Review Article| Volume 43, ISSUE 2, P195-202, May 2016

Testosterone and Male Infertility

Published:March 19, 2016DOI:https://doi.org/10.1016/j.ucl.2016.01.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sharlip I.D.
        • Jarow J.P.
        • Belker A.M.
        • et al.
        Best practice policies for male infertility.
        Fertil Steril. 2002; 77: 873-882
        • Sigman M.
        • Jarow J.P.
        Endocrine evaluation of infertile men.
        Urology. 1997; 50: 659-664
        • Practice Committee of American Society for Reproductive Medicine
        Diagnostic evaluation of the infertile male: a committee opinion.
        Fertil Steril. 2012; 98: 294-301
        • Coviello A.D.
        • Matsumoto A.M.
        • Bremner W.J.
        • et al.
        Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
        J Clin Endocrinol Metab. 2005; 90: 2595-2602
        • Seminara S.B.
        • Oliveira L.M.
        • Beranova M.
        • et al.
        Genetics of hypogonadotropic hypogonadism.
        J Endocrinol Invest. 2000; 23: 560-565
        • Tsai P.S.
        • Gill J.C.
        Mechanisms of disease: insights into X-linked and autosomal-dominant Kallmann syndrome.
        Nat Clin Pract Endocrinol Metab. 2006; 2: 160-171
        • Hershkovitz E.
        • Loewenthal N.
        • Peretz A.
        • et al.
        Testicular expressed genes are missing in familial X-Linked Kallmann syndrome due to two large different deletions in daughter's X chromosomes.
        Horm Res. 2008; 69: 276-283
        • Leroy C.
        • Fouveaut C.
        • Leclercq S.
        • et al.
        Biallelic mutations in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome.
        Eur J Hum Genet. 2008; 16: 865-868
        • Dode C.
        • Hardelin J.P.
        Kallmann syndrome.
        Eur J Hum Genet. 2009; 17: 139-146
        • Sigman M.
        Assisted reproductive technics for the treatment of male factor infertility.
        R I Med J. 1991; 74: 591-596
        • Cassidy S.B.
        • Driscoll D.J.
        Prader-Willi syndrome.
        Eur J Hum Genet. 2009; 17: 3-13
        • Burman P.
        • Ritzen E.M.
        • Lindgren A.C.
        Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH.
        Endocr Rev. 2001; 22: 787-799
        • Smeets D.F.
        • Hamel B.C.
        • Nelen M.R.
        • et al.
        Prader-Willi syndrome and Angelman syndrome in cousins from a family with a translocation between chromosomes 6 and 15.
        N Engl J Med. 1992; 326: 807-811
        • Burris T.P.
        • Guo W.
        • McCabe E.R.
        The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily.
        Recent Prog Horm Res. 1996; 51 ([discussion: 259–60]): 241-259
        • Bedecarrats G.Y.
        • Kaiser U.B.
        Mutations in the human gonadotropin-releasing hormone receptor: insights into receptor biology and function.
        Semin Reprod Med. 2007; 25: 368-378
        • Huhtaniemi I.
        The Parkes lecture. Mutations of gonadotrophin and gonadotrophin receptor genes: what do they teach us about reproductive physiology?.
        J Reprod Fertil. 2000; 119: 173-186
        • Wu R.H.
        • Rosenfeld R.
        • Fukushima D.
        Hypogonadism and Leydig cell hypoplasia unresponsive to human luteinizing hormone (hLH).
        Am J Med Sci. 1984; 287: 23-25
        • Wu S.M.
        • Hallermeier K.M.
        • Laue L.
        • et al.
        Inactivation of the luteinizing hormone/chorionic gonadotropin receptor by an insertional mutation in Leydig cell hypoplasia.
        Mol Endocrinol. 1998; 12: 1651-1660
        • Gillam M.P.
        • Molitch M.E.
        • Lombardi G.
        • et al.
        Advances in the treatment of prolactinomas.
        Endocr Rev. 2006; 27: 485-534
        • Shimon I.
        • Benbassat C.
        • Hadani M.
        Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
        Eur J Endocrinol. 2007; 156: 225-231
        • De Rosa M.
        • Ciccarelli A.
        • Zarrilli S.
        • et al.
        The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
        Clin Endocrinol (Oxf). 2006; 64: 307-313
        • Urban M.D.
        • Lee P.A.
        • Migeon C.J.
        Adult height and fertility in men with congenital virilizing adrenal hyperplasia.
        N Engl J Med. 1978; 299: 1392-1396
        • Hammoud Z.
        • Tan B.
        • Badve S.
        • et al.
        Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.
        Endocr Relat Cancer. 2008; 15: 475-483
        • Giagulli V.A.
        • Kaufman J.M.
        • Vermeulen A.
        Pathogenesis of the decreased androgen levels in obese men.
        J Clin Endocrinol Metab. 1994; 79: 997-1000
        • Globerman H.
        • Shen-Orr Z.
        • Karnieli E.
        • et al.
        Inhibin B in men with severe obesity and after weight reduction following gastroplasty.
        Endocr Res. 2005; 31: 17-26
        • Kaukua J.
        • Pekkarinen T.
        • Sane T.
        • et al.
        Sex hormones and sexual function in obese men losing weight.
        Obes Res. 2003; 11: 689-694
        • Tchernof A.
        • Despres J.P.
        • Belanger A.
        • et al.
        Reduced testosterone and adrenal C19 steroid levels in obese men.
        Metabolism. 1995; 44: 513-519
        • Oates R.D.
        Clinical and diagnostic features of patients with suspected Klinefelter syndrome.
        J Androl. 2003; 24: 49-50
        • Klinefelter H.F.
        Syndrome characterized by gynecomastia, aspermatogenesis without a-leydigism, and increased excretion of follicle-stimulating hormone.
        J Clin Endocrinol Metab. 1942; 2: 615-624
        • Therman E.
        Human chromosomes: structure, behavior, and effects.
        Springer-Verlag, New York1993
        • Madgar I.
        • Dor J.
        • Weissenberg R.
        • et al.
        Prognostic value of the clinical and laboratory evaluation in patients with nonmosaic Klinefelter syndrome who are receiving assisted reproductive therapy.
        Fertil Steril. 2002; 77: 1167-1169
        • Schiff J.D.
        • Palermo G.D.
        • Veeck L.L.
        • et al.
        Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome.
        J Clin Endocrinol Metab. 2005; 90: 6263-6267
        • Westlander G.
        • Ekerhovd E.
        • Granberg S.
        • et al.
        Testicular ultrasonography and extended chromosome analysis in men with nonmosaic Klinefelter syndrome: a prospective study of possible predictive factors for successful sperm recovery.
        Fertil Steril. 2001; 75: 1102-1105
        • Komori S.
        • Horiuchi I.
        • Hamada Y.
        • et al.
        Birth of healthy neonates after intracytoplasmic injection of ejaculated or testicular spermatozoa from men with nonmosaic Klinefelter's syndrome: a report of 2 cases.
        J Reprod Med. 2004; 49: 126-130
        • Ron-El R.
        • Raziel A.
        • Strassburger D.
        • et al.
        Birth of healthy male twins after intracytoplasmic sperm injection of frozen-thawed testicular spermatozoa from a patient with nonmosaic Klinefelter syndrome.
        Fertil Steril. 2000; 74: 832-833
        • Layton J.B.
        • Li D.
        • Meier C.R.
        • et al.
        Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011.
        J Clin Endocrinol Metab. 2014; 99: 835-842
        • Baume N.
        • Mahler N.
        • Kamber M.
        • et al.
        Research of stimulants and anabolic steroids in dietary supplements.
        Scand J Med Sci Sports. 2006; 16: 41-48
        • Geyer H.
        • Parr M.K.
        • Koehler K.
        • et al.
        Nutritional supplements cross-contaminated and faked with doping substances.
        J Mass Spectrom. 2008; 43: 892-902
        • Corona G.
        • Monami M.
        • Rastrelli G.
        • et al.
        Testosterone and metabolic syndrome: a meta-analysis study.
        J Sex Med. 2011; 8: 272-283
        • Corona G.
        • Rastrelli G.
        • Monami M.
        • et al.
        Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study.
        Eur J Endocrinol. 2011; 165: 687-701
        • Zarrouf F.A.
        • Artz S.
        • Griffith J.
        • et al.
        Testosterone and depression: systematic review and meta-analysis.
        J Psychiatr Pract. 2009; 15: 289-305
        • Sagoe D.
        • Molde H.
        • Andreassen C.S.
        • et al.
        The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis.
        Ann Epidemiol. 2014; 24: 383-398
        • Coward R.M.
        • Rajanahally S.
        • Kovac J.R.
        • et al.
        Anabolic steroid induced hypogonadism in young men.
        J Urol. 2013; 190: 2200-2205
        • Kovac J.R.
        • Scovell J.
        • Ramasamy R.
        • et al.
        Men regret anabolic steroid use due to a lack of comprehension regarding the consequences on future fertility.
        Andrologia. 2015; 47: 872-878
        • Samplaski M.K.
        • Loai Y.
        • Wong K.
        • et al.
        Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters.
        Fertil Steril. 2014; 101: 64-69
        • Turek P.J.
        • Williams R.H.
        • Gilbaugh 3rd, J.H.
        • et al.
        The reversibility of anabolic steroid-induced azoospermia.
        J Urol. 1995; 153: 1628-1630
        • Anderson R.A.
        • Wu F.C.
        Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
        J Clin Endocrinol Metab. 1996; 81: 896-901
      1. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility.
        Lancet. 1990; 336: 955-959
        • Depenbusch M.
        • von Eckardstein S.
        • Simoni M.
        • et al.
        Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone.
        Eur J Endocrinol. 2002; 147: 617-624
        • Hsieh T.C.
        • Pastuszak A.W.
        • Hwang K.
        • et al.
        Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
        J Urol. 2013; 189: 647-650
        • Vicari E.
        • Mongioi A.
        • Calogero A.E.
        • et al.
        Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism–long-term follow-up.
        Int J Androl. 1992; 15: 320-329
        • Wenker E.P.
        • Dupree J.M.
        • Langille G.M.
        • et al.
        The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use.
        J Sex Med. 2015; 12: 1334-1337
        • Kliesch S.
        • Behre H.M.
        • Nieschlag E.
        Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male.
        Fertil Steril. 1995; 63: 1326-1328
        • Bouloux P.M.
        • Nieschlag E.
        • Burger H.G.
        • et al.
        Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone.
        J Androl. 2003; 24: 604-611
        • Liu P.Y.
        • Turner L.
        • Rushford D.
        • et al.
        Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men.
        Hum Reprod. 1999; 14: 1540-1545
        • Matsumoto A.M.
        • Snyder P.J.
        • Bhasin S.
        • et al.
        Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.
        Fertil Steril. 2009; 92: 979-990